Efficacy and safety of recombinant human activated protein C for severe sepsis.
- G. Bernard, J. Vincent, C. Fisher
- MedicineNew England Journal of Medicine
- 2001
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
- E. Ziegler, C. Fisher, N. Teng
- Medicine, BiologyNew England Journal of Medicine
- 14 February 1991
HA-1A is safe and effective for the treatment of patients with sepsis and gram-negative bacteremia and analyses that stratified according to the severity of illness at entry showed improved survival with HA- 1A treatment in both severely ill and less severely ill patients.
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.
- R. Bone, C. Fisher, T. Clemmer, G. Slotman, C. Metz, R. Balk
- MedicineNew England Journal of Medicine
- 10 September 1987
It is concluded that the use of high-dose corticosteroids provides no benefit in the treatment of severe sepsis and septic shock.
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
- C. Fisher, J. Agosti, E. Benjamin
- MedicineNew England Journal of Medicine
- 27 June 1996
In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.
Sepsis syndrome: a valid clinical entity
- R. Bone, C. Fisher, T. Clemmer, G. Slotman, C. Metz, R. Balk
- Medicine
- 1 May 1989
The sepsis syndrome represents a systemic response to infection and is defined as hypothermia or hyperthermia, tachycardia, tachypnea, clinical evidence of an infection site and with at least one end-organ demonstrating inadequate perfusion or dysfunction expressed as poor or altered cerebral function.
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis…
If rhIL-1ra treatment has any therapeutic activity in severe sepsis, the incremental benefits are small and will be difficult to demonstrate in a patient population as defined by this clinical trial.
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
- E. Abraham, M. Matthay, J. Repine
- Medicine, PsychologyCritical Care Medicine
- 1 January 2000
An important challenge is to progress from clinical syndromes to more specific entities that are delineated by alterations in specific immunologic or biochemical pathways, which will provide more homogeneous groups of patients who can be identified at early stages of their clinical course.
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
- C. Fisher, J. Dhainaut, D. Stablein
- Medicine
- 15 June 1994
Primary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater.
Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.
Current evidence provides no support for the use of corticosteroids in patients with sepsis or septic shock, and suggests that their use may be harmful, underscore the need for future methodologically rigorous trials evaluating new immune-modulating therapies in well-defined critically ill patients with overwhelming infection.
Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
The murine monoclonal anti-TNF antibody was well tolerated despite the development of anti-murine antibodies in 98% of patients and no survival benefit was found for the total study population.
...
...